0001209191-22-039692.txt : 20220628 0001209191-22-039692.hdr.sgml : 20220628 20220628194804 ACCESSION NUMBER: 0001209191-22-039692 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220624 FILED AS OF DATE: 20220628 DATE AS OF CHANGE: 20220628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PURA VIDA INVESTMENTS, LLC CENTRAL INDEX KEY: 0001590144 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37648 FILM NUMBER: 221051480 BUSINESS ADDRESS: STREET 1: 512 W 22ND STREET STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10011 BUSINESS PHONE: 646-597-6995 MAIL ADDRESS: STREET 1: 512 W 22ND STREET STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10011 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kamen Efrem CENTRAL INDEX KEY: 0001789193 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37648 FILM NUMBER: 221051479 MAIL ADDRESS: STREET 1: C/O PURA VIDA INVESTMENTS, LLC STREET 2: 512 W 22ND STREET, 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10011 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oncocyte Corp CENTRAL INDEX KEY: 0001642380 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 271041563 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-409-7600 MAIL ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20200213 FORMER COMPANY: FORMER CONFORMED NAME: Oncocyte Corp DATE OF NAME CHANGE: 20200205 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20150513 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-24 0 0001642380 Oncocyte Corp OCX 0001590144 PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET 7TH FLOOR NEW YORK NY 10011 0 0 1 0 0001789193 Kamen Efrem C/O PURA VIDA INVESTMENTS, LLC 512 W 22ND STREET, 7TH FLOOR NEW YORK NY 10011 0 0 1 0 Common Stock 2022-06-24 4 S 0 10964 1.0514 D 7462643 I By Pura Vida Master Fund, Ltd. Common Stock 2022-06-24 4 S 0 35441 1.0269 D 7427202 I By Pura Vida Master Fund, Ltd. Common Stock 2022-06-24 4 S 0 12517 1.0514 D 8520146 I By the Managed Accounts. Common Stock 2022-06-24 4 S 0 40464 1.0269 D 8479682 I By the Managed Accounts. Aggregate number of shares sold on the same date at difference prices. Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.04 to $1.09, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Securities and Exchange Commission staff (the "Staff), Issuer or any security holder, upon request. Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any. Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.02 to $1.0475, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Although these sales are matchable transactions to purchases on April 14, 2022 under Section 16(b) of the Securities Exchange Act of 1934, as amended, the sales prices are less than the purchase prices, constituting a loss and, as such, there are no profits to disgorge pursuant to Section 16(b). /s/ Efrem Kamen, Managing Member of Pura Vida Investments, LLC 2022-06-28 /s/ Efrem Kamen 2022-06-28